AN2 Therapeutics
NASDAQ: ANTXFounded 2019 · Incorporated in Delaware · 6 known investors
AN2 Therapeutics develops a pipeline of boron-based compounds intended as therapeutics for hematology, infectious disease, and oncology. The company focuses on drugs addressing unmet medical needs to improve patient health outcomes.
BiotechHealthtech
Investors · 6
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
A2 Biotherapeutics13 shared keywordsA2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform for both autologous and allogeneic applications. The company targets cancer and other serious diseases and advances its therapies through clinical trials.
Companies competing with AN2 Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does AN2 Therapeutics do?
- AN2 Therapeutics develops a pipeline of boron-based compounds intended as therapeutics for hematology, infectious disease, and oncology. The company focuses on drugs addressing unmet medical needs to improve patient health outcomes.
- Who are AN2 Therapeutics's investors?
- AN2 Therapeutics's investors include Adjuvant Capital, BioRock Ventures, Flucas Ventures, Mountain Group Capital, RA Capital, Hatteras Venture Partners.